ZHEJIANG JIUZHOU PHARMACEUTICAL CO.,LTD.

Jiuzhou Pharma is a global CDMO specialising in small-molecule and peptide API development, process optimisation, analyt...

实验室 Laboratory

• 联系人： -
• 联系电话： -
• 电子邮箱： -
• 企业地址： No.99 Waisha Road, Jiaojiang Taizhou city, Zhejiang, 318000 China
• 所在州省： Zhejiang
• 企业官网： -
• 企业类型： -
• 员工人数： -
• 企业税号： -
• 年营业额： -
• 最后更新： 2026-03-23
• 企业简介：
  Jiuzhou Pharma is a global CDMO specialising in small-molecule and peptide API development, process optimisation, analytical services, and GMP manufacturing. Our laboratories provide route-scouting, scalable process development, solid-state characterisation, and full analytical method development and validation services. We support advanced chemistry including asymmetric catalysis, flow chemistry, fluorination, enzymatic catalysis, cryogenic and high-pressure reactions, and HPAPI development (OEB4/OEB5). Our peptide laboratories offer SPPS and LPPS synthesis, purification, characterisation, and lyophilisation for research through development, to full-scale commercial supply. Solid-state capabilities include polymorph screening, crystallisation development, and salt-form selection. Jiuzhou’s GMP facilities enable seamless scale-up from milligram to commercial tonnes, supported by a full CMC and regulatory team experienced with global filings (DMF, CEP, ANDA, IND). We also provide early formulation development for oral solid dose and semi-solid products. We offer integrated DS–DP services, rapid technology transfer, cost-efficient manufacturing in a mature GMP network, and reliable global supply to more than 90 countries. State of the art Process R & D facility at our Konstanz site in Germany. Small but rapidly growing team of top European PhD Chemists. High -throughput and -data workflow makes this team highly competitive and fast. Particular expertise in small molecule new route identification and development, and route optimisation. Jiuzhou Pharma’s ESG strategy is anchored in science-based GHG reduction targets, renewable energy adoption, supply-chain engagement, robust governance, and international benchmarks and recognitions. Our framework reflects best practices in the pharmaceutical sector for environmental and social responsibility. As evidenced by external independent recognition: Inclusion in the FTSE4Good Index, improved ESG ratings from the London Stock Exchange Group, EcoVadis Gold Medal, AA rating from Wind, validation of GHG emission targets by the SBTi.
• 主营产品：